Distinct Pharmacodynamic Complement Biomarker Signatures Define Iptacopan and Pegcetacoplan Treatment in C3 Glomerulopathy. (PubMed, Kidney Int Rep) - Oct 21, 2026 - "Pathway-based biomarker assessment may distinguish expected treatment effects from incomplete or discordant biochemical control. These categories describe PD patterns rather than clinical efficacy and require validation against clinical outcomes."
Biomarker • Journal • PK/PD data • Complement-mediated Rare Disorders • Glomerulonephritis • Transplantation
|
|
Angela F M Nelson; Anna R Carmen; Carla M Nester; Didier Mandelbrot; Dingwu Shao; Hector Martin Merinero; Kameron Kruger; Neetika Garg; Nicole C Meyer Horning; Renee X Goodfellow; Richard J H Smith; Sarah M Roberts; Sydney S Jellison; Yuzhou Zhang
|